IL29465A - Crosslinked kallikrein inactivator and its production - Google Patents
Crosslinked kallikrein inactivator and its productionInfo
- Publication number
- IL29465A IL29465A IL2946568A IL2946568A IL29465A IL 29465 A IL29465 A IL 29465A IL 2946568 A IL2946568 A IL 2946568A IL 2946568 A IL2946568 A IL 2946568A IL 29465 A IL29465 A IL 29465A
- Authority
- IL
- Israel
- Prior art keywords
- inactivator
- kallikrein
- fractions
- production
- succinimidic
- Prior art date
Links
- 230000000937 inactivator Effects 0.000 title claims description 17
- 108060005987 Kallikrein Proteins 0.000 title claims description 16
- 102000001399 Kallikrein Human genes 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 238000000034 method Methods 0.000 claims description 8
- 229920005654 Sephadex Polymers 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 239000013638 trimer Substances 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 150000001409 amidines Chemical class 0.000 claims description 2
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 5
- 239000001384 succinic acid Substances 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 101710081722 Antitrypsin Proteins 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000001475 anti-trypsic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- -1 ester hydrochloride Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 108700041430 link Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Refrigerator Housings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEF0051832 | 1967-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL29465A true IL29465A (en) | 1971-12-29 |
Family
ID=7104937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL2946568A IL29465A (en) | 1967-03-16 | 1968-02-13 | Crosslinked kallikrein inactivator and its production |
Country Status (13)
| Country | Link |
|---|---|
| AT (1) | AT283588B (OSRAM) |
| BE (1) | BE712280A (OSRAM) |
| CH (1) | CH486493A (OSRAM) |
| DE (1) | DE1670820A1 (OSRAM) |
| DK (1) | DK119270B (OSRAM) |
| ES (1) | ES351635A1 (OSRAM) |
| FI (1) | FI46970C (OSRAM) |
| FR (1) | FR1565575A (OSRAM) |
| GB (1) | GB1173861A (OSRAM) |
| IL (1) | IL29465A (OSRAM) |
| NL (1) | NL6803643A (OSRAM) |
| NO (1) | NO120839B (OSRAM) |
| SE (1) | SE342241B (OSRAM) |
-
1967
- 1967-03-16 DE DE19671670820 patent/DE1670820A1/de active Pending
-
1968
- 1968-02-12 CH CH203368A patent/CH486493A/de not_active IP Right Cessation
- 1968-02-13 IL IL2946568A patent/IL29465A/en unknown
- 1968-02-28 FI FI53368A patent/FI46970C/fi active
- 1968-03-04 AT AT207468A patent/AT283588B/de active
- 1968-03-12 NO NO95368A patent/NO120839B/no unknown
- 1968-03-14 NL NL6803643A patent/NL6803643A/xx unknown
- 1968-03-14 GB GB1245968A patent/GB1173861A/en not_active Expired
- 1968-03-14 DK DK109168A patent/DK119270B/da unknown
- 1968-03-15 BE BE712280D patent/BE712280A/xx unknown
- 1968-03-15 ES ES351635A patent/ES351635A1/es not_active Expired
- 1968-03-15 SE SE344868A patent/SE342241B/xx unknown
- 1968-03-15 FR FR1565575D patent/FR1565575A/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB1173861A (en) | 1969-12-10 |
| DK119270B (da) | 1970-12-07 |
| NL6803643A (OSRAM) | 1968-09-17 |
| NO120839B (OSRAM) | 1970-12-14 |
| FI46970B (OSRAM) | 1973-05-02 |
| FR1565575A (OSRAM) | 1969-05-02 |
| BE712280A (OSRAM) | 1968-09-16 |
| CH486493A (de) | 1970-02-28 |
| ES351635A1 (es) | 1969-06-16 |
| AT283588B (de) | 1970-08-10 |
| SE342241B (OSRAM) | 1972-01-31 |
| FI46970C (fi) | 1973-08-10 |
| DE1670820A1 (de) | 1971-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7741274B2 (en) | Casein derived peptides and uses thereof in therapy | |
| Bourin et al. | Glycosaminoglycans and the regulation of blood coagulation | |
| Sunyer et al. | Multiple forms of complement C3 in trout that differ in binding to complement activators. | |
| US20070203060A1 (en) | Casein Derived Peptides And Therapeutic Uses Thereof | |
| DK150204B (da) | Analogifremgangsmaade til fremstilling af dipeptidyl-agmatiner eller deres hydrochlorider | |
| CA1335375C (en) | Glycosaminoglycan salts, processes for the preparation thereof and pharmaceutical composition containing them | |
| JPH0625202B2 (ja) | デキストラン誘導体 | |
| Rasmussen et al. | Localization of two interchain disulfide bridges in dimers of bovine αs2‐casein: Parallel and antiparallel alignments of the polypeptide chains | |
| WO1993005167A1 (en) | Cell-type specific heparan sulfate proteoglycans and their uses | |
| BR112021008797A2 (pt) | Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame | |
| US5538946A (en) | Hirudin derivatives with delayed action | |
| US7666996B2 (en) | Casein derived peptides and uses thereof | |
| US6815535B1 (en) | Purification of fibrinogen | |
| EP0546096B1 (en) | Macrophage activating factor from vitamin d binding protein | |
| Watanabe et al. | Primary structure of a base non-specific and adenylic acid preferential ribonuclease from Aspergillus saitoi | |
| Avgerinos et al. | Production and clinical development of a Hansenula polymorpha-derived PEGylated hirudin | |
| Pigman et al. | The occurrence of repetitive glycopeptide sequences in bovine submaxillary glycoprotein | |
| Rudman et al. | Isolation of two lipolytic pituitary peptides | |
| IL29465A (en) | Crosslinked kallikrein inactivator and its production | |
| Benaim et al. | Comparative phosphorylation of calmodulin from trypanosomatids and bovine brain by calmodulin-binding protein kinases | |
| Boyer | Extraordinary incidence of electrophoretically silent genetic polymorphisms | |
| US5795868A (en) | Platelet aggregation inhibitors | |
| Cheung et al. | Vitamin K-dependent carboxylase: structural requirements for propeptide activation | |
| EP2274329A1 (en) | Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | |
| Adelstein et al. | The interaction of platelet actin, myosin and myosin light chain kinase |